C84.67 Anaplastic large cell lymphoma, ALK-positive, spleen

Name of the Condition

• Anaplastic large cell lymphoma, ALK-positive, spleen (ICD-10 Code: C84.67)

Summary

Anaplastic large cell lymphoma, ALK-positive, spleen (ALCL, ALK-positive) is a rare subtype of non-Hodgkin lymphoma that primarily affects T-lymphocytes. It is characterized by the presence of the anaplastic lymphoma kinase (ALK) protein, resulting from a specific genetic rearrangement. This condition typically presents as a rapidly growing tumor involving the spleen. ALCL, ALK-positive is more common in children and young adults and is generally considered aggressive but responsive to targeted therapies.

Causes

The exact cause of ALK-positive ALCL is not fully understood. The disease is driven by a genetic translocation involving the ALK gene, most commonly the t(2;5)(p23;q35) translocation, which results in overexpression of the ALK protein. This abnormal protein promotes uncontrolled cell growth and survival. While the translocation is a key driver, other genetic mutations may contribute to disease development, though specific environmental triggers remain unclear.

Risk Factors

• Age: More common in children and young adults, with a peak incidence in the second and third decades of life.
• Gender: Slightly higher prevalence in males.
• Genetic factors: Presence of the ALK translocation is a primary risk factor.
• Immunosuppression: Weakened immune systems may increase risk.

Symptoms

Symptoms may include abdominal pain or discomfort, splenomegaly (enlarged spleen), fatigue, unexplained weight loss, fever, and night sweats. Some patients may experience systemic symptoms such as pruritus (itching) or lymphadenopathy (swollen lymph nodes) if the disease spreads beyond the spleen.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or MRI of the abdomen), and tissue biopsy of the spleen. Pathological examination confirms the presence of ALK-positive ALCL, often using immunohistochemistry to detect the ALK protein. Additional tests, such as flow cytometry or genetic analysis, may be performed to rule out other conditions and assess disease extent.

Treatment Options

Treatment typically includes systemic therapies such as chemotherapy, targeted therapy (e.g., ALK inhibitors), or immunotherapy. The choice of treatment depends on the stage of the disease, patient age, and overall health. In some cases, splenectomy (surgical removal of the spleen) may be considered, especially if the spleen is significantly enlarged or causing symptoms.

Prognosis and Follow-Up

Prognosis varies based on disease stage, response to treatment, and individual patient factors. ALK-positive ALCL generally has a better prognosis than ALK-negative subtypes, with many patients achieving remission. Follow-up care includes regular monitoring with imaging and blood tests to detect recurrence. Long-term surveillance is recommended, as late relapses can occur.

Complications

Complications may include splenic rupture, infection due to splenectomy or immunosuppression, and progression to other organs. Systemic symptoms like fever or weight loss may persist if the disease is not controlled. Rarely, the condition can transform into a more aggressive form or resist treatment.

Lifestyle & Prevention

There are no known lifestyle changes to prevent ALK-positive ALCL. Maintaining overall health, including a balanced diet and regular exercise, may support immune function. Avoiding known carcinogens and managing immunosuppression (if applicable) is advisable, though specific preventive measures are limited.

When to Seek Professional Help

Seek medical attention if you experience persistent abdominal pain, unexplained weight loss, fever, or fatigue. Prompt evaluation is important if you have a history of lymphoma or notice a rapidly enlarging spleen. Early diagnosis and treatment improve outcomes.

Tips for Medical Coders

When coding for C84.67, ensure the documentation specifies the spleen as the primary site of involvement. Verify that the diagnosis aligns with ALK-positive status, as this distinguishes it from other lymphoma subtypes. Confirm that no additional site modifiers (e.g., lymph nodes, skin) are documented, as these would require different codes. Accurate clinical documentation is essential for correct code assignment.